Sernova (TSE:SVA) Trading Down 2.2% – Here’s Why

Sernova Corp. (TSE:SVA)’s share price fell 2.2% during mid-day trading on Thursday . The stock traded as low as C$0.23 and last traded at C$0.23. 135,401 shares changed hands during trading, a decline of 18% from the average session volume of 164,533 shares. The stock had previously closed at C$0.23.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently commented on SVA shares. Leede Financial reduced their target price on shares of Sernova from C$3.00 to C$1.50 and set a “speculative buy” rating for the company in a report on Friday, September 13th. Ventum Financial decreased their target price on Sernova from C$3.00 to C$2.50 and set a “buy” rating on the stock in a research report on Friday, September 13th. Finally, Ventum Cap Mkts upgraded shares of Sernova to a “strong-buy” rating in a research report on Thursday, September 12th.

Sernova Price Performance

The company has a fifty day simple moving average of C$0.25 and a two-hundred day simple moving average of C$0.28. The company has a debt-to-equity ratio of 16.55, a quick ratio of 18.11 and a current ratio of 0.32. The company has a market capitalization of C$74.82 million, a price-to-earnings ratio of -1.77 and a beta of 1.35.

Sernova (TSE:SVA) last posted its quarterly earnings data on Monday, September 16th. The company reported C($0.02) EPS for the quarter, beating analysts’ consensus estimates of C($0.03) by C$0.01. As a group, research analysts anticipate that Sernova Corp. will post -0.08 earnings per share for the current year.

Sernova Company Profile

Sernova Corp. operates as a clinical-stage regenerative medicine therapeutics company in Canada. The company focuses on the development and commercialization of regenerative medicine therapeutics, including its proprietary Cell Pouch and associated technologies consisting of therapeutic cells and local cellular immune protection.